

Special Issue

Focus on Antimicrobial Resistance: Research and Recent Advances

Message from the Guest Editors

Public health is worldwide threatened by the phenomenon of antimicrobial resistance (AMR), and in particular, by the emergence of new multi-resistant bacterial strains. The strategy to be adopted to prevent, reduce, and mitigate AMR should include a multi-sectoral approach, able to integrate preventive strategies (i.e., vaccines, diagnostic tools) with innovative and effective therapies (i.e., novel antibiotics, monoclonal antibodies, bacteriophages, microbiota). To this aim, the Special Issue “Focus on Antimicrobial Resistance: research and recent advances” welcomes any contribution in the following research areas that tackle AMR from different perspectives:

- Potential targets for antimicrobial drug development;
- Novel antimicrobial leads;
- Next-generation vaccines against drug-resistant pathogens;
- Microbiota-based strategies to prevent infections;
- Diagnostic methods for molecular detection of resistance determinants;
- Use of surrogate organisms (i.e., Zebrafish, *Caenorhabditis elegans*, etc.) as simpler models to elucidate host–pathogen interactions;
- Omics technologies for the study of AMR;
- Computational analysis of host-pathogen interaction networks.

Guest Editors

Dr. Laura Morelli

Dr. Giuseppe D'Orazio

Dr. Federica Compostella

Deadline for manuscript submissions

closed (29 February 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/165654

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).